In May, Mindmaze transferred part of its assets and 60 employees, almost all of its workforce, in a new structure funded by a “consortium of American and Swiss investors”. A decision taken by the first Swiss, and Vaudoise unicorn (start-up valued at more than $ 1 billion), after a component placement. This Tuesday, Neurox, his heiress, and the Geneva Biotech Relief Therapeutics announced through a press release their intention to bring together a merger by the end of the year.
This merger should allow Neurox to be listed at the Six Swiss Exchange. At the end of the operation, relief shareholders should hold around 9% of the shares in the combined entity while the remaining 91% would return to the shareholders of Neurox. According to the document published by the two companies, the Geneva Biotech is valued up to 100 million francs while the Vaudoise company is estimated at 1 billion francs. The value chosen for therapeutics relief represents “a significant premium compared to its current market capitalization”, said the press release. The action was exchanged at 2.75 francs at the end of the day on Tuesday, after an increase of almost 17% following the announcement.
